Grace Therapeutics (GRCE) Other Non-Current Assets (2018 - 2022)
Grace Therapeutics (GRCE) posted Other Non-Current Assets of $352000.0 for Q4 2022, little changed sequentially from $352000.0 in Q3 2022, and down 40.03% YoY from $587000.0 in Q4 2021.
Grace Therapeutics (GRCE) Other Non-Current Assets (2018 - 2022) Analysis & Trends
Grace Therapeutics has reported Other Non-Current Assets for 5 years, with the latest figure at $352000.0 in Q4 2022.
- Quarterly Other Non-Current Assets fell 40.03% year-over-year to $352000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $352000.0 (down 40.03% YoY) and the FY2022 annual result came in at $352000.0, down 54.17% from the prior year.
- Other Non-Current Assets steadied at $352000.0 in Q4 2022 per GRCE's latest filing, from $352000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $2.6 million in Q1 2020 and troughed at $192000.0 in Q2 2020.
- A 5-year average of $725016.7 and a median of $554201.8 in 2018 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2020 and 2021: Other Non-Current Assets surged 515.52% in 2020, then plunged 70.21% in 2021.
- Over 5 years, Other Non-Current Assets stood at $521403.5 in 2018, then slipped by 19.67% to $418830.2 in 2019, then jumped by 159.77% to $1.1 million in 2020, then tumbled by 46.05% to $587000.0 in 2021, then plunged by 40.03% to $352000.0 in 2022.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $352000.0, $352000.0, and $352000.0 for Q4 2022, Q3 2022, and Q2 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 62.96 Mn |
| 10 | Grace Therapeutics | 37.82 Mn | 37.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 352,000.00 |
| Sep 30, 2022 | 352,000.00 |
| Jun 30, 2022 | 352,000.00 |
| Mar 31, 2022 | 352,000.00 |
| Dec 31, 2021 | 587,000.00 |
| Sep 30, 2021 | 764,000.00 |
| Jun 30, 2021 | 778,000.00 |
| Mar 31, 2021 | 768,000.00 |
| Dec 31, 2020 | 1.09 Mn |
| Sep 30, 2020 | 1.05 Mn |
| Jun 30, 2020 | 192,000.00 |
| Mar 31, 2020 | 2.58 Mn |
| Mar 31, 2019 | 418,830.20 |
| Mar 31, 2018 | 521,403.52 |